Product Description
a highly selective GABA A-alpha5 negative allosteric modulator (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33833333/)
Mechanisms of Action: GABA5 NAM
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-003791-13 | P2 |
Active, not recruiting |
Other |
2026-05-05 |